Morningstar Investment Management LLC Sells 27,852 Shares of AbbVie Inc. $ABBV

Posted by George Bondi on May 26th, 2026

Morningstar Investment Management LLC trimmed its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 81.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,441 shares of the company’s stock after selling 27,852 shares during the quarter. Morningstar Investment Management LLC’s holdings in AbbVie were worth $1,472,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Chelsea Counsel Co. bought a new position in AbbVie in the third quarter valued at approximately $26,000. Westend Capital Management LLC bought a new position in AbbVie in the fourth quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie in the third quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID increased its stake in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC boosted its position in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after buying an additional 85 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Piper Sandler raised their target price on shares of AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Evercore set a $235.00 target price on shares of AbbVie in a research report on Friday, May 15th. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. William Blair restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Royal Bank Of Canada assumed coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.43.

Check Out Our Latest Stock Analysis on ABBV

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $216.02 on Tuesday. The firm has a market cap of $381.65 billion, a PE ratio of 106.41, a price-to-earnings-growth ratio of 0.74 and a beta of 0.32. The firm’s fifty day moving average is $208.53 and its 200-day moving average is $219.73. AbbVie Inc. has a 52 week low of $181.71 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.46 earnings per share. Sell-side analysts forecast that AbbVie Inc. will post 14.3 EPS for the current year.

Insider Buying and Selling at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by insiders.

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.